Arrivent Biopharma logo

Arrivent Biopharma Share Price Today

(NASDAQ: AVBP)

Arrivent Biopharma share price is $22.47 & ₹1,954.19 as on 6 Mar 2025, 2.30 'hrs' IST

$22.47

0.52

(2.35%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Arrivent Biopharma share price in Dollar and Rupees. Guide to invest in Arrivent Biopharma stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Arrivent Biopharma, along with analyst recommendations, forecasts, and comprehensive financials.

Arrivent Biopharma share price movements

  • Today's Low: $22.00
    Today's High: $22.75

    Day's Volatility :3.32%

  • 52 Weeks Low: $14.35
    52 Weeks High: $36.37

    52 Weeks Volatility :60.54%

Arrivent Biopharma (AVBP) Returns

PeriodArrivent Biopharma, Inc.Index (Russel 2000)
3 Months
-21.3%
0.0%
6 Months
-15.53%
0.0%
1 Year
10.96%
0.0%
3 Years
12.35%
-11.6%

Arrivent Biopharma (AVBP) Key Statistics

in dollars & INR

Previous Close
$21.955
Open
$22.92
Today's High
$22.75
Today's Low
$21.995
Market Capitalization
$746.8M
Today's Volume
$154.9K
52 Week High
$36.37
52 Week Low
$14.35
Revenue TTM
$0.0
Earnings Per Share (EPS)
$-2.61
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-36.07%

How to invest in Arrivent Biopharma Stock (AVBP) from India?

It is very easy for Indian residents to invest directly in Arrivent Biopharma from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Arrivent Biopharma stock in both Indian Rupees (INR) and US Dollars (USD). Search for Arrivent Biopharma or AVBP on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Arrivent Biopharma or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Arrivent Biopharma shares which would translate to 0.039 fractional shares of Arrivent Biopharma as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Arrivent Biopharma, in just a few clicks!

Returns in Arrivent Biopharma (AVBP) for Indian investors in Rupees

The Arrivent Biopharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Arrivent Biopharma investment value today

Current value as on today

₹1,15,912

Returns

₹15,912

(+15.91%)

Returns from Arrivent Biopharma Stock

₹10,963 (+10.96%)

Dollar Returns

₹4,949 (+4.95%)

Indian investors sentiment towards Arrivent Biopharma (AVBP)

-75%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Arrivent Biopharma Stock from India on INDmoney has decreased by -75% in the last 30 days, reflecting a downward trend in search activity.

Analyst Recommendation on Arrivent Biopharma

Buy

    90%Buy

    9%Hold

    0%Sell

Based on 11 Wall street analysts offering stock ratings for Arrivent Biopharma(by analysts ranked 0 to 5 stars)

Analyst Forecast on Arrivent Biopharma Stock (AVBP)

What analysts predicted

Upside of 71.78%

Target:

$38.60

Current:

$22.47

Insights on Arrivent Biopharma Stock (Ticker Symbol: AVBP)

  • Price Movement

    In the last 7 days, AVBP stock has moved down by -5.2%
  • AVBP vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.5% return, outperforming this stock by 55.5%

Arrivent Biopharma Technicals Summary

Sell

Neutral

Buy

Arrivent Biopharma is currently in a neutral trading position according to technical analysis indicators.

Arrivent Biopharma (AVBP) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Arrivent Biopharma, Inc. logo
-20.31%
-15.53%
10.96%
12.35%
12.35%
Regeneron Pharmaceuticals, Inc. logo
-1.42%
-40.28%
-29.31%
11.08%
44.83%
Beone Medicines Ltd logo
17.63%
36.87%
64.37%
45.89%
71.3%
Vertex Pharmaceuticals Incorporated logo
1.94%
4.92%
19.37%
108.73%
123.83%
Alnylam Pharmaceuticals, Inc. logo
-8.03%
-0.89%
66.53%
52.9%
126.66%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Arrivent Biopharma, Inc. logo
NA
NA
NA
-2.69
-0.36
-0.25
NA
8.24
Regeneron Pharmaceuticals, Inc. logo
17.86
17.86
1.01
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.34
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Arrivent Biopharma, Inc. logo
Buy
$746.8M
12.35%
NA
0.0%
Regeneron Pharmaceuticals, Inc. logo
Buy
$73.8B
44.83%
17.86
31.07%
Beone Medicines Ltd logo
NA
$29.1B
71.3%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$124.9B
123.83%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.4B
126.66%
NA
-12.37%

About Arrivent Biopharma

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Organization
Arrivent Biopharma
Employees
40
CEO
Dr. Zhengbin Yao Ph.D.
Industry
Miscellaneous

Management People of Arrivent Biopharma

NameTitle
Dr. Zhengbin Yao Ph.D.
Co-Founder, Chairman, President & CEO
Dr. Stuart Lutzker M.D., Ph.D.
Co-Founder, President of Research & Development and Director
Ms. Robin LaChapelle M.A.
Co-Founder & COO
Mr. Winston Kung M.B.A.
CFO & Treasurer
Ms. Yang Wang Ph.D.
Chief Technology Officer
Mr. James Paul Kastenmayer J.D., Ph.D.
General Counsel & Secretary
Ms. Meghna Chowdary
Senior Vice President of Commercial Strategy

Important FAQs about investing in AVBP Stock from India :

What is Arrivent Biopharma share price today?

Arrivent Biopharma share price today stands at $22.47, Open: $22.92 ; Previous Close: $21.96 ; High: $22.75 ; Low: $22.00 ; 52 Week High: $36.37 ; 52 Week Low: $14.35.

The stock opens at $22.92, after a previous close of $21.96. The stock reached a daily high of $22.75 and a low of $22.00, with a 52-week high of $36.37 and a 52-week low of $14.35.

Can Indians buy Arrivent Biopharma shares?

Yes, Indians can invest in the Arrivent Biopharma (AVBP) from India.

With INDmoney, you can buy Arrivent Biopharma at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Arrivent Biopharma at zero transaction cost.

How can I buy Arrivent Biopharma shares from India?

It is very easy to buy Arrivent Biopharma from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Arrivent Biopharma (AVBP) be purchased?

Yes, you can buy fractional shares of Arrivent Biopharma with INDmoney app.

What are the documents required to start investing in Arrivent Biopharma stocks?

To start investing in Arrivent Biopharma, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Arrivent Biopharma Stock (AVBP)?

Today’s highest price of Arrivent Biopharma (AVBP) is $22.75.

Today’s lowest price of Arrivent Biopharma (AVBP) is $22.00.

What is today's market capitalisation of Arrivent Biopharma?

Today's market capitalisation of Arrivent Biopharma AVBP is 746.8M

What is the 52 Week High and Low Range of Arrivent Biopharma Stock (AVBP)?

  • 52 Week High

    $36.37

  • 52 Week Low

    $14.35

What are the historical returns of Arrivent Biopharma (AVBP)?

  • 1 Month Returns

    -20.31%

  • 3 Months Returns

    -15.53%

  • 1 Year Returns

    10.96%

  • 5 Years Returns

    12.35%

Who is the Chief Executive Officer (CEO) of Arrivent Biopharma ?

Dr. Zhengbin Yao Ph.D. is the current Chief Executive Officer (CEO) of Arrivent Biopharma.